Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines

Leukemia and Lymphoma

Volumn 51, Issue 2, 2010, Pages 297-303

  Peng, Chun Yan ^a   Jiang, Jikai ^a   Zheng, Hai Tao ^a   Liu, Xiao Shan ^a  

^a SHANTOU UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Combination index method of Chou and Talalay; DNA methylation; Epigenetic therapeutic agents; Leukemia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; TRICHOSTATIN A; VALPROIC ACID;

ARTICLE; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG ANTAGONISM; DRUG INDICATION; DRUG POTENTIATION; EPIGENETICS; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ANTINEOPLASTIC AGENTS; ARSENICALS; AZACITIDINE; CELL PROLIFERATION; CELL SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA, NEOPLASM; DRUG ANTAGONISM; DRUG SYNERGISM; ELECTROPHORESIS, CAPILLARY; GROWTH INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; K562 CELLS; LEUKEMIA; OXIDES; U937 CELLS; VALPROIC ACID;

EID: 76349106912     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903486212     Document Type: Article

References (37)

1. Bestor TH, Chandler VL, Feinberg AP. Epigenetic effects in eukaryotic gene expression. Dev Genet 1994;15:458-462.
2. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463.
3. Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003;22:6489-6496.
4. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006;20:1-13.
5. Petti MC,Mandelli F, Zagonel V, et al. Pilot study of 5-aza-20-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993;7(Suppl 1):36-41.
6. Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112:981-989.
7. Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 2007;13:4225-4232.
8. Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94:3978-3983.
9. Bonati A, Rizzoli V, Lunghi P. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 2006;7:397-405.
10. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-3353.
11. Aposhian HV. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Ann Rev Pharmacol Toxicol 1997;37:397-419.
12. Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene P53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 1997;386:263-277.
13. Chai CY, Huang YC, Hung WC, Kang WY, Chen WT. Arsenic salts induced autophagic cell death and hypermethylation of DAPK promoter in SV-40 immortalized human uroepithelial cells. Toxicol Lett 2007;173:48-56.
14. Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K, Hirano S. Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 2006;37:298-311.
15. Ramirez T, Brocher J, Stopper H, Hock R. Sodium arsenite modulates histone acetylation, histone deacetylase activity and HMGN protein dynamics in human cells. Chromosoma 2008;117:147-157.
16. Zhou X, Sun H, Ellen TP, Chen H, Costa M. Arsenite alters global histone H3 methylation. Carcinogenesis 2008;29: 1831-1836.
17. Chen G, Wang Y, Huang H, et al. Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur J Haematol 2009;82:176-183.
18. Fraga MF, Rodriquez R, Canal MJ. Rapid quantification of DNA methylation by high performance capillary electrophoresis. Electrophoresis 2000;21:2990-2994.
19. Van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002;16:1362-1371.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
21. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-1524.
22. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749.
23. Sciandrello G, Caradonna F, Mauro M, Barbata G. Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells. Carcinogenesis 2004;25:413-417.
24. Reichard JF, Schnekenburger M, Puga A. Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem Biophys Res Commun 2007;352:188-192.
25. Okoji RS, Yu RC, Maronpot RR, Froines JR. Sodium arsenite administration via drinking water increases genome-wide and Ha-ras DNA hypomethylation in methyl-deficient C57BL/6J mice. Carcinogenesis 2002;23:777-785.
26. Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol Appl Pharmacol 2001;175:260-268.
27. Tong H, Lin M. Arsenic trioxide induced p15INK4B gene expression in myelodysplastic syndrome cell line MUTZ-1. Chinese J Hematol 2002;23:638-641.
28. Fu HY, Sheng JZ, Sheng SF, Zhou HR. n-MSP detection of p16 gene demethylation and transcription in human multiple myeloma U266 cell line induced by arsenic trioxide. J Exp Hematol 2007;15:79-85.
29. Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood 1980;56:344-350.
30. Hellebreker DM, Griffioen AW, van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta 2007;1775:76-91.
31. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-17179.
32. Topaly J, ZellerWJ, Fruehauf S. Synergistic activity of the new ABL specifictyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001;15:342-347.
33. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000;183:145-154.
34. Zhu J, Lallemand-Breitenbach V, de The H. Pathways of retinoic acid-or arsenic trioxide-induced PML/RARa catabolism, role of oncogene degradation in disease remission. Oncogene 2001;20:7257-7265.
35. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-20-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-3279.
36. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005;4:1993-2000.
37. Carraway HE, Gore SD. Addition of histone deacetylase inhibitors in combination therapy. J Clin Oncol 2007;25: 1955-1956. .